<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla., Nov. 5, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial, which was presented as a Late Breaking Clinical Trial at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation.
...read full article on PRNewsWire
